about
Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 TVirological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.Management of hepatitis C in liver transplant recipients.Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionInterferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.Chronic hepatitis B infection.Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents.Successful combined liver/kidney transplantation from a donor with Pompe disease.Intravascular Ultrasound in the Creation of Transhepatic Portosystemic Shunts Reduces Needle Passes, Radiation Dose, and Procedure Time: A Retrospective Study of a Single-Institution Experience.Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.Risk stratification for Hepatitis B treatment in the molecular ageAntiviral therapy in liver transplant recipients: is SVR the only endpoint that matters?Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.Hepatocellular carcinoma surveillance: a national survey of current practices in the USA.Non-cirrhotic portal hypertension due to 6-mercaptopurine use for Crohn's disease.Unexpectedly low immunocompetence in transplant patients on ketoconazoleNovel concept for easy quantification of posttransplant immunocompetence
P50
Q33787851-B2FE8D25-918F-4A1E-8284-56E89F74875FQ35928048-4E815BCD-B367-46F8-87BA-3B2EBEFD00CFQ36382060-F3187A1E-E22B-4E33-A1A0-C9D5B0177A97Q36392142-380D3CCE-2CE2-44D1-8B9C-CB6A027BF854Q36505470-FBE5800F-F45F-410F-9682-DD5CEAB31BE3Q37552703-5C0E6E87-157F-4C58-A1CB-E8470EA68E6DQ38006145-3A3A83F0-1D7F-4BF4-9205-A605C4C37CD7Q38210490-251C1510-92E7-47E7-B3CB-13059F23C988Q38511088-C7A5589A-F2CB-44EA-BF8C-E9DE97C72ED5Q40813944-9C4C3764-9A74-4551-983D-6FC1B48BE354Q41222268-45DC45A9-E58D-47CE-BA75-D3D16F083D47Q41724402-AC70197B-40C3-4EB9-A529-E8B1E45DBC30Q41955722-1D729D58-61D8-4B6D-9E95-7C4E0B67747EQ43035139-129D2BF0-C1FA-4FAF-A8B8-2BDD8999E61AQ44797474-61D146C1-DF87-4E5C-90ED-480181D29E62Q45342209-BEE48FA5-9921-4D9D-A244-71F5A33ABD05Q45992699-259B6479-D786-468B-B59A-FED99FD3DE94Q73964328-BF608B54-AC32-4416-BDC7-C641C37385C8Q74685623-6CCFA6F8-4FA1-48B3-9333-5D4B802FCD5B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alexander Kuo
@ast
Alexander Kuo
@en
Alexander Kuo
@es
Alexander Kuo
@nl
Alexander Kuo
@sl
type
label
Alexander Kuo
@ast
Alexander Kuo
@en
Alexander Kuo
@es
Alexander Kuo
@nl
Alexander Kuo
@sl
prefLabel
Alexander Kuo
@ast
Alexander Kuo
@en
Alexander Kuo
@es
Alexander Kuo
@nl
Alexander Kuo
@sl
P106
P21
P31
P496
0000-0002-9106-8865